Virtus Biotech ETF
13 hedge funds and large institutions have $3.85M invested in Virtus Biotech ETF in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 2 closing their positions.
5% more capital invested
Capital invested by funds: $3.68M → $3.85M (+$168K)
0.13% more ownership
Funds ownership: 18.58% → 18.71% (+0.13%)
7% less funds holding
Funds holding: 14 → 13 (-1)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$168K |
| 2 |
IFG
Independent Financial Group
San Diego,
California
|
+$64.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$40.8K |
| 5 |
JP Morgan Chase
New York
|
+$557 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$136K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$33.4K |
| 3 |
DSC
Duncker Streett & Co
St. Louis,
Missouri
|
-$30.2K |
| 4 |
TSMHT
Thurston Springer Miller Herd & Titak
Indianapolis,
Indiana
|
-$28.3K |
| 5 |
Goldman Sachs
New York
|
-$27.9K |
BBP Hedge Fund Activity: Q2 2024 in Review
13 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q2 2024, worth a combined $3.85M — up 4.6% from $3.68M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BBP and 1 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.
The largest buyer was Raymond James Financial Services Advisors, adding an estimated $168K. The largest seller was Morgan Stanley, cutting an estimated $136K.
- 13 institutional investors held Virtus Biotech ETF (BBP) as of Q2 2024, down from 14 in Q1 2024.
- Funds reported $3.85M of Virtus Biotech ETF stock for Q2 2024, up 4.6% quarter-over-quarter.
- 1 fund opened new Virtus Biotech ETF positions in Q2 2024 and 2 closed out, a net change of -1 holder.
- The largest Virtus Biotech ETF buyer in Q2 2024 was Raymond James Financial Services Advisors, an estimated $168K added.
- The largest Virtus Biotech ETF seller in Q2 2024 was Morgan Stanley, an estimated $136K sold.
Based on aggregated 13F filings for Q2 2024.